N末端前脑钠肽原作为慢性阻塞性肺疾病患者肺动脉高压的一种新型生物标志物。
NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD.
作者信息
Avdeev Sergey N, Gaynitdinova Viliya V, Merzhoeva Zamira M, Nuralieva Galiya S, Tarabrin Evgeniy A, Berikkhanov Zelimkhan G, Nikitina Lidiya Y, Gneusheva Tatiana Y, Sokolova Elizaveta S, Ainetdinov Rifat M, Proshkina Anna A, Ataman Kirill S, Ma Qingyun
机构信息
Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
National Medical Research Center of Pulmonology, I.M. Sechenov First, Moscow State Medical University (Sechenov University), Moscow, Russia.
出版信息
Sci Rep. 2025 Jul 1;15(1):21169. doi: 10.1038/s41598-025-08059-2.
To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP < 40 mmHg, = 42) and group of patients with PH (SPAP ≥40 mmHg, = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, < 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP ( = 0.77, < 0.001), mMRC dyspnea score ( = 0.42, = 0.001), CAT score ( = 0.60, < 0.001), and SpO ( = − 0.47, = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.
评估慢性阻塞性肺疾病（COPD）患者的N端前体C型利钠肽（NT-proCNP）血浆水平，并评估其对COPD患者肺动脉高压（PH）的诊断价值。根据收缩期肺动脉压（SPAP）范围，将COPD患者分为无PH组（SPAP < 40 mmHg，n = 42）和有PH组（SPAP≥40 mmHg，n = 52）。有PH和无PH的患者NT-proCNP水平存在显著差异（3.63±0.95 pg/mL对1.42±0.35 pg/mL，P < 0.001）。NT-proCNP水平与SPAP（r = 0.77，P < 0.001）、mMRC呼吸困难评分（r = 0.42，P = 0.001）、CAT评分（r = 0.60，P < 0.001）和SpO₂（r = -0.47，P = 0.001）之间存在统计学显著相关性。COPD患者的肺动脉高压与较高的血浆NT-proCNP水平相关。
Zotero 插件